Tegaserod, a potential inhibitor of YTHDF1, can block the direct binding of YTHDF1 with m6A-modified mRNAs and inhibit YTHDF1-regulated cyclin E2 translation, which results in reduced viability of patient-derived AML cells in vitro (146). This evidence concerns the gene YTHDF1 and acute myeloid leukemia.